ERM is a member of the ETS transcription factor family. High levels of the corresponding mRNA are detected in a variety of human breast cancer cell lines, as well as in aggressive human breast tumors. As ERM protein is almost undetectable in these cells, high degradation of this transcription factor has been postulated. Here we have investigated whether ERM degradation might depend on the proteasome pathway. We show that endogenous and ectopically expressed ERM protein is short-lived protein and undergoes proteasome-dependent degradation. Deletion mutagenesis studies indicate that the 61 C-terminal amino acids of ERM are critical for its proteolysis and serve as a degradation signal. Although ERM conjugates with ubiquitin, this post-translational modification does not depend on the C-terminal domain. We have used an Ets-responsive ICAM-1 reporter plasmid to show that the ubiquitin-proteasome pathway can affect transcriptional function of ERM. Thus, ERM is subject to degradation via the 26S proteasome pathway, and this pathway probably plays an important role in regulating ERM transcriptional activity.
Introduction
Covalent modification of proteins by ubiquitin (Ub) creates new proteins with unique protein surfaces that can mediate a range of protein-protein interactions. Three different types of enzymes constitute the Ub pathway: E1 activating enzymes, E2 conjugating enzyme and E3 ligases important for establishing reaction specificity (Pickart, 2001) . In most cases, numerous cycles of ubiquitination result in the formation of long polyubiquitin chains on the target protein; these are recognized by the 26S proteasome as a signal for destruction. Interestingly, other roles have recently been proposed for ubiquitination, including regulation of transcription factor activity (Lipford and Deshaies, 2003; Muratani and Tansey, 2003) . Numerous transcription factors are reported to undergo Ub modification, including the transcription factor PEA3/E1AF (Takahashi et al., 2005) . This factor and also ERM and ER81 belong to the PEA3 group of Ets transcription factors, which possess a common DNA-binding domain of about 85 residues binding the consensus core sequence 5 0 -GGAA/T-3 0 (for a review, see Sharrocks, 2001 ). The PEA3 group members are involved in a variety of developmental processes, such as gland organogenesis through epithelium/mesenchyme interactions (Chotteau-Lelie`vre et al., 1997 . In pathological processes, the presence of ERM mRNA has been associated with breast cancer metastasis. High levels of this messenger are detected in human and mouse (Galang et al., 2004) metastatic mammary cancer cells. In vivo, in mouse mammary tumors producing high levels of ERM mRNA, ectopic expression of a dominant-negative Ets mutant increases the mouse survival rate (Shepherd et al., 2001) . Recently, we have also shown on a large series of primary breast cancers that ERM gene expression is an adverse prognostic factor for overall survival (Chotteau Lelie`vre et al., 2004) . In these studies, data on ERM protein levels are scant because of the difficulty of detecting the protein. Rapid protein degradation might explain this observation, but no significant information is available on the stability and degradation of Ets-family proteins.
In the present study, we have investigated whether ERM stability is regulated in cells. We show that this factor undergoes rapid degradation via the 26S proteasome pathway and that this instability is related to a degradation signal located in the C-terminal extremity of ERM. We also show that ERM is ubiquitinated and that this post-translational modification may enhance the transcriptional activity of the protein.
Results

ERM is a short-lived protein regulated by the proteasome
We have previously shown that ERM mRNA is present at high levels in most human breast cancer cell lines. Yet, ERM protein is hardly detectable in these cell lines, even those displaying the highest levels of ERM mRNA, such as MDA-MB-231 . As illustrated in Figure 1a , detection was achieved after immunoprecipitation from extracts of cells that had been metabolically labeled with [
35 S]methionine, as the protein was nearly undetectable in lysates by immunoblotting (Figure 1b) . It is often also difficult to detect ERM protein after ectopic expression, probably because of its rapid degradation in cells. To test this hypothesis, we estimated ERM turnover in MDA-MB-231 cells by pulse-chase analysis. For this purpose, ERM was immunoprecipitated after pulse-labeling with [ 35 S]methionine followed by chasing with unlabeled methionine. As shown in Figure 1a , ERM is in fact a highly unstable protein with a half-life of 30-60 min.
Degradation of transcription factors occurs predominantly via the 26S proteasome pathway (Dalton, 2004) . To investigate whether this pathway plays an important role in the degradation of ERM, we examined the effect of the proteasome-specific inhibitor MG132. MDA-MB-231 cells were treated with the inhibitor and the level of ERM protein was estimated by Western blotting with antibody raised against ERM. Although ERM protein was nearly undetectable in the absence of inhibitor, treatment of cells with MG132 resulted in a dramatic accumulation of the endogenous protein ( Figure 1b) . Similar experiments were performed with U2OS cells expressing ERM ectopically. As observed for endogenous ERM in MDA-MB-231 cells, ERM protein produced by ectopic gene expression was poorly detected in transfected U2OS cells, and in the presence of MG132, its level dramatically increased (Figure 1c) . Two other specific proteasome inhibitors, ALLN and lactacystin, also caused the steady-state level of ERM to increase significantly (Figure 1c ). These results indicate that ERM protein is degraded under basal conditions via the proteasome pathway both in cells where ERM gene expression is endogenous and in cells where the gene is exogenously expressed.
ERM undergoes ubiquitination in vivo
We next wondered whether ERM might become a proteasome target as a consequence of polyubiquitin modification. To test this hypothesis, we co-transfected COS-7 cells transiently with a vector expressing the ERM coding sequence and a construct coding for His 6 -tagged Ub. The cells were then incubated with or without the proteasome inhibitor ALLN, used to block degradation of Ub-modified protein. The cells were finally harvested in denaturing lysis buffer, and Ubmodified proteins isolated on nickel agarose (Ni-NTA) were analysed by Western blotting with anti-ERM antibody. As seen in Figure 2a , a major ERM species was observed at about 85 kDa in the Ni-NTA-bound protein fraction as a result of Ub overproduction (left panel, compare lanes 1 and 2); this species was enhanced, like unconjugated ERM in the crude extract, by inhibition of the proteasome with ALLN (lane 3). In addition to this Ub-ERM conjugate, a high molecular mass smear, characteristic of polyubiquitination, was also detected in the presence of the proteasome inhibitor (more exposed blot, Figure 2a strongly suggests that polyubiquitination of ERM precedes its proteosomal degradation. Thus far, we have been unable to detect this modification in untransfected cells, presumably because of limited expression of the relevant ERM species at the endogenous protein level. Indeed, as judged for the results of transfection-mediated overexpression, only a small fraction of ERM was found to be ubiquitinated. The same was also observed for ERM sumoylation (Degerny et al., 2005) .
The apparent molecular weight of the major ubiquitinated ERM species is about 15 kDa higher than that of unmodified ERM (about 70 kDa). As the apparent molecular weight of His 6 -tagged Ub is about 11 kDa, it is likely that this ERM species is a mono-ubiquitinated ERM form. To confirm this hypothesis, we repeated the experiment described above, replacing the construct coding for His 6 -tagged Ub with a construct supporting the synthesis of a mutant Ub characterized by a lysineto-arginine substitution at either position 48 (Ub K 48 R) or position 63 (Ub K 63 R). Residues 48 and 63 are involved in the assembly of polyubiquitin chains; their mutation renders Ub unable to form these chains with other Ub molecules and favors mono-ubiquitination. In these experiments, although mutation of K 63 had no effect, mutation of K 48 was found to affect ERM ubiquitination by increasing the level of the 85-kDa modified ERM species as compared to the level observed with wt Ub (Figure 2b, upper panel) . In contrast, the total level of ERM protein in cell extracts was the same whether wt or mutated Ub was present (Figure 2b, lower panel) . This is consistent with the hypothesis that the 85-kDa ERM species corresponds to mono-ubiquitinated ERM form(s) and suggests that K 48 in Ub plays a role in ERM polyubiquitination. Interestingly, K 48 -linked polyubiquitin chains are believed to function as a signal designating substrates as proteasome targets, whereas K 63 -linked polyubiquitin chains have a regulatory function that does not involve proteolysis (Pickart, 2004) . It must however be noted that in these experiments, expression of Ub K 48 R did not lead to a decrease of the higher molecular weight Ubmodified ERM forms. As shown in Figure 2c , similar observation was also made when p53 was used in place of ERM in same experiments. It cannot be ruled out that such results may reflect mono-ubiquitination of the proteins at multiple sites and/or polyubiquitination at one or multiple sites owing to the competition of exogenously expressed Ub with the endogenous Ub pool.
ERM contains a degradation domain
A major determinant of protein instability is the presence of degradation signals. To identify such regions in ERM, we generated a series of ERM deletion mutants. Figure 3a shows the portion of the coding sequence remaining in each mutant. To examine the stability of the truncated ERM proteins, we transfected U2OS cells with the plasmids expressing the mutant constructs and treated them or not with the proteasome inhibitor ALLN. Steady-state ERM levels were then examined by Western blotting with anti-ERM antibodies, the level of actin being used to normalize for sample loading. Using the same concentration of each expression plasmid for transfection, we found that, as for full-length ERM, cellular levels of all N-terminally truncated mutants were low in the absence of proteasome inhibitor and significantly higher in the presence of inhibitor (Figure 3a, lanes 1-8) . Similarly, ERM lacking the DNA-binding domain (ERMD328-444, lanes 9-10) was detected at a much lower level in the absence than in the presence of ALLN. In contrast, each mutant lacking the C-terminal domain encompassing residues 449-510 26S proteasome and transcriptional factor of ERM J-L Baert et al (Ct) was detected at a relatively high level, whether the proteasome inhibitor was added or not (lanes 11-16). In keeping with this observation, deletion of the central domain (residues 90-293) did not influence ERM stability, but further deletion of the C-terminal domain clearly increased the level of mutated protein, which remained nearly constant in the presence of ALLN ( Figure 3a , right panel). Altogether, these data suggest that ERM degradation depends on the C-terminal domain of the protein. To further confirm that protein stability is responsible for the differences observed between wt and C-terminally deleted ERM, U2OS cells transfected with a plasmid coding for wt or C-terminally truncated ERM were treated with cycloheximide to block new protein synthesis, and the stability of the remaining protein was determined by immunoblotting with anti-ERM antibody. We showed that, like endogenous ERM, exogenously expressed wt ERM is rapidly degraded (Figure 3b ). After 40 min of cycloheximide treatment, the detected level of full-length protein was significantly reduced in cells not treated with ALLN but not in cells treated with the inhibitor. In contrast, the amount of ERM protein lacking the C-terminal domain (ERMDCt, Figure 3b ) remained more constant over time whether ALLN was present or not, indicating that the increased level of the truncated protein results from its stabilization. Taken together, these results indicate that rapid turnover of ERM requires the presence of a degradation domain in the C-terminal part of the protein.
Stabilization of C-terminally truncated ERM is not owing to decreased ubiquitination
The C-terminal region of ERM contains a single lysine residue (K 468 ) that might be a critical site for ubiquitination leading to ERM degradation via the Ub-proteasome pathway. To investigate the potential role of K 468 in ERM turnover, we examined the effect of the K 468 R mutation on the stability of ERM. The detected level of ERM K 468 R was similar to that observed for wt ERM when cells were transfected with equal amounts of ERM-expressing plasmid and treated or not with ALLN. Furthermore, this mutation did not reduce the level of ubiquitinated ERM in cell extracts (data not shown), thus indicating that the instability of ERM is not related to ubiquitination of the C-terminal part of the protein. Another possibility is that this C-terminal region might contain specific motifs enabling the protein to recruit E3 Ub ligase that would subsequently tag other sites with polyubiquitin chains (Laney and Hochstrasser, 1999) . To test this hypothesis, we compared in COS cells the overall ubiquitination level of wt ERM with that of the C-terminally truncated protein. We found no difference in ubiquitination between wt and truncated ERM (Figure 4a ). The major band for ubiquitinated truncated ERM was found at about 75 kDa. As shown above (Figure 2b ) for wt ERM, the amount of this Ub conjugate increased significantly when wt Ub was replaced with Ub K 48 R, but not when it was replaced with Ub K 63 R (Figure 4b ). Altogether, these results indicate that the major Ub-modified form of C-terminally truncated ERM is mono-ubiquitinated and that the C-terminal region of ERM is not essential for ubiquitination of the protein.
The region spanning the 61 C-terminal amino acids of ERM must thus contain a signal that targets the protein for degradation by the proteasome and is apparently ubiquitination independent. To determine whether this domain can act as an independent signal for ERM processing, we constructed a fusion protein in which the yeast Gal4 DNA-binding domain (Gal4) is fused to the C-terminal domain of ERM (Gal4-Ct ERM). As previously described, cells were transfected with a plasmid encoding Gal4 or Gal4-Ct ERM and extracts of these cells were subjected to Western blot analysis. Steady-state levels of both proteins were determined in the presence and absence of ALLN. As illustrated in Figure 5 , Gal4 accumulated to a fairly high level whether ALLN was present or not. This agrees with the observation that the DBD of Gal4 is relatively stable (Tworkowski et al., 2002) . In contrast, Gal4-Ct ERM accumulated to a significantly lower level in the absence of proteasome inhibitor but to an increased level in its presence. This indicates that Gal4-Ct ERM, in contrast to Gal4 alone, is rapidly degraded via a proteasomedependent mechanism. To examine whether this Gal4-Ct ERM instability is related to ubiquitination, we transfected cells as above with a plasmid expressing His-Ub and treated the cells with ALLN. In the His-Ubenriched fraction obtained by affinity chromatography of cell extracts on Ni 2 þ beads, neither Gal4 nor Gal4-Ct ERM was detected by Western blot analysis with antiGal4 antibody (or with anti-ERM antibody for Gal4-Ct ERM) ( Figure 5, lane 3) . In contrast, the unstable ERM 276-510 containing the ETS DNA-binding domain and the C-terminal region of ERM was clearly ubiquitinated under the same conditions ( Figure 5 , right panel). Thus, ubiquitination of the fusion protein seems not to be required for its recognition by the proteasomedependent system.
Ubiquitination of ERM and transcriptional activity
Finally, we sought to determine whether the proteasome pathway affects ERM-mediated transactivation. We measured luciferase activities owing to the presence of the Ets-responsive ICAM-1 reporter construct after cotransfection of RK13 cells with this construct and ERM expression vectors (Figure 6a ), followed by incubation with or without ALLN. Figure 6b shows that treatment with the inhibitor resulted in about a twofold increase in ERM activity, as compared to the control. As ALLN increases ERM stability and thus the ERM level (Figure 6c , upper panel), this increase might merely reflect the greater amount of ERM present in ALLNtreated cells. Yet as illustrated in Figure 6c (lower panel), no luciferase activity increase was observed in the absence of ALLN when the amount of ERM expression plasmid used exceeded the 10 ng used in the above experiment. It would thus seem that proteasome Figure 5
The C-terminal domain of ERM is sufficient to target proteins for rapid proteosomal degradation. A construct encoding the Gal4 DNA-binding domain, alone (Gal4) or fused to the Cterminal domain of ERM (Gal4-Ct ERM), was expressed in COS-7 cells for 24 h with a construct coding for His 6 -tagged Ub. The cells were treated or not (as indicated) for 5 h with ALLN. An aliquot of total cell extract was analyed by Western blotting with anti-Gal4 (Gal4 and Gal4-Ct ERM) or anti-ERM antibody ).
Extracts of cells treated with ALLN were incubated with Ni 2 þ -NTA agarose beads and the bound fractions were analysed as described above. Similar results were obtained when the Gal4-Ct ERM fusion protein was detected with anti-ERM antibody. 26S proteasome and transcriptional factor of ERM J-L Baert et al inhibition can increase ERM-mediated transactivation independently of its ERM-stabilizing effect. Similar experiments were performed on cells co-transfected with the same reporter plasmid and a plasmid expressing an ERM mutant lacking either the N-terminal or the C-terminal transactivation domain. As previously described (Janknecht et al., 1996) , both truncated proteins showed reduced transcriptional activity. Yet only the C-terminal deletion mutant displayed (about twofold) increased transcriptional activity after ALLN treatment (Figure 6b ). It is interesting that ALLN has little effect on the level of C-terminal deletion mutant but it does affect its activity, whereas the same treatment markedly increases the level of N-terminally truncated protein (Figure 3 ) without significantly altering its activity.
To rule out the possibility that the observed effects of ALLN are nonspecific, similar experiments were performed with another proteasome inhibitor, MG132. As illustrated in Figure 6d for wt ERM, this inhibitor also increased ERM transactivation by twofold. On the other hand, the ALLN or MG132 treatment did not significantly affect the transcription driven by the CMV, SV40 or EF1a promoter, indicating that proteasome inhibitor treatment does not interfere with luciferase activity under the conditions of our assay and that activation of ERM-mediated transcription is specific (Figure 6e ). Altogether, these experiments suggest that the observed effects of the proteasome inhibitors on ERM-dependent transcription reflect a change in transactivation potential rather than merely ERM stabilization. Furthermore, these data indicate that the ALLN-triggered increase in ERM activity is mediated by the N-terminal transactivation domain. ALLN treatment not only increases the ERM protein level but also enhances the degree of ubiquination of the protein. To determine whether the degree of ubiquitination affects ERM transcriptional activity, we compared the activity of ERM in cells cotransfected with an ERMexpressing plasmid and a plasmid expressing either wt Ub or one of the two Ub mutants, K 48 R or K 63 R Ub. As shown above, the level of ubiquitinated ERM is higher in the presence of K 48 R Ub than in the presence of either K 63 R Ub or wt Ub (both of these yielding similar results) (see Figure 2b ). Is this reflected in the transcriptional activity of ERM? As shown in Figure 7 , ERM as well as its N-and C-terminally truncated mutants displayed similar activities in the presence of wt or K 63 R Ub. The presence of K 48 R Ub, however, was found to affect ERM-mediated transcription. Indeed, a 60% increase in luciferase activity was observed with both full-length and C-terminally truncated ERM, whereas the activity of N-terminally truncated ERM was unaffected. Altogether, these data suggest that ubiquitination of ERM may be a mechanism resulting in transcriptional activation independent of the C-terminal transactivation domain. Accordingly, we failed to detect significant change in the activity of this domain fused to the DBD of Gal4 either following treatment by the proteasome inhibitors ALLN and MG132 or by the expression of K 48 R Ub (Figure 8 ).
Discussion
We show here that the ERM transcription factor is a highly unstable protein with a half-life of 30-60 min. This instability appears both in MDA-MB-231 cells, where ERM synthesis is endogenous, and in COS-7, U2OS and RK13 cells expressing exogenous ERM. The two other PEA3 group members, ER81 and E1AF, also show short half-lives when overproduced (Goel and Janknecht, 2003; Takahashi et al., 2005) . Yet the halflives determined for these proteins, exceeding 2 h, are somewhat longer than the ERM half-life determined here. This may reflect a real difference in stability among the PEA3-group members or merely different experimental approaches and/or cell types analysed. It should be noted that in MDA-MB-231 cells expressing all three group members, we found a similar half-life for ER81 and ERM (not shown). It is thus likely that at least ERM and its closest relative ER81 have a very similar turnover rate. ERM is a short-lived protein like many transcription factors. The rapid turnover of these regulatory proteins is necessary to keep their intracellular levels low and responsive to environmental stimuli (Conaway et al., 2002; Muratani and Tansey, 2003) . In fact, it is now established that the proteasome system plays a major role in the rapid elimination of these transcription factors (Ciechanover et al., 2000) . Among the PEA3-group transcription factors, only overproduced E1AF protein has been shown to be stabilized by proteasome inhibition (Takahashi et al., 2005) . We show here that endogenous and exogenous ERM steady-state levels and the ERM half-life increase in the presence of proteasome inhibitors, indicating that the proteasome is important in the control of cellular ERM levels.
An interesting finding of this study is that the C-terminal domain of ERM seems to be essential for rapid protein degradation. The ERM mutant lacking this domain (amino acids 449-510) displays increased stability in all cell lines tested here. Protein stabilization 
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is not owing to removal of a critical ubiquitination site. Nor, as shown previously (Janknecht et al., 1996) , is it owing to an altered localization of the mutant protein.
In fact, the C-terminal domain of ERM is sufficient for acceleration of proteolysis, as its fusion to a heterologous protein significantly destabilizes that protein. We therefore propose, for the first time, that this domain acts as a degradation signal. Degradation signals are multiple and generally increase the turnover of a protein by recruiting a Ub ligase, that is, an enzyme that conjugates Ub to the substrate (Laney and Hochstrasser, 1999) . We show here, however, that removal of the C-terminal domain does not significantly affect the level of Ub conjugation to ERM. The mechanism leading to ERM instability may thus be largely independent of ubiquitination and might involve direct interaction of the C-terminal region of ERM with the proteasome. Such a mechanism has been demonstrated in the case of p21 Cip1 and IkBa, which bind respectively to subunit C8 or C3 of the 20S proteasome (Touitou et al., 2001; Alvarez-Castelao and Castano, 2005) . Alternatively, proteasome recognition might involve a cofactor as shown for ODC. Degradation of ODC depends on the presence of an antizyme which enhances the ODCproteasome association (Murakami et al., 1999; Zhang et al., 2003) . The fact remains, however, that ERM does undergo ubiquitination, so we cannot exclude a role for this process in proteosomal degradation of the protein.
For instance a Ub-modified site might serve as a proteasome recognition element, the C-terminal domain being an initiation site for efficient proteasome-mediated degradation. In keeping with this view, a recent study has demonstrated that, although many proteins are marked for destruction by attachment of a polyubiquitin chain that directs binding to the proteasome, a region of the substrate must also be recognized in order for proteolytic engagement, leading to rapid degradation, to begin (Prakash et al., 2004) . The substrate region required for engagement must be unstructured. Interestingly, structural predictions obtained with different algorithms reveal that the C-terminal region of ERM may be unstructured or only slightly structured.
In some unstable transcription factors, investigators report an overlap between sequences that activate transcription and those that signal degradation, so that the transcriptional activity of these proteins is coupled to their proteolytic destruction (Molinari et al., 1999; Salghetti et al., 2000; Muratani and Tansey, 2003) . In ERM, likewise, deletion of the C-terminal domain previously characterized as a transactivation domain (TAD) (Laget et al., 1996) affects both the ability to transactivate and the rate of degradation. Yet ERM contains a second TAD, which has been mapped to the N-terminal part of the protein (amino acids 1-72; Laget et al., 1996; Defossez et al., 1997) . Curiously, although deletion of the N-terminal TAD severely affects the transcriptional activity of ERM, it does not improve its stability. The degradation signal is thus apparently restricted to the C-terminal TAD of ERM, and inhibition of ERM transcriptional activity is not necessarily sufficient to prevent rapid degradation of the protein.
There is increasing evidence that ubiquitination and proteasome-mediated degradation of transcription factors are closely linked to the transactivating function of these factors. It has recently been demonstrated that inhibition of proteosomal degradation enhances the transcriptional response mediated by some nuclear receptors (Blanquart et al., 2002; Deroo et al., 2002; Pollenz, 2002) and the Ets protein E1AF (Takahashi et al., 2005) . We show here that blocking protein turnover with the proteasome inhibitor ALLN or MG132 also induces a change in ERM transcriptional activity. Enhanced ERM-mediated transactivation was observed only when the N-terminal TAD was present; it appeared unrelated to the increase in the level of native protein owing to proteasome inhibition. A similar effect was achieved by expressing a Ub mutant, K 48 R, which reinforces mono-ubiquitination of ERM. As proteasome inhibitor also causes accumulation of Ub-conjugated ERM, including the mono-ubiquitinated form, it might be suggested that ubiquitination, and particularly mono-ubiquitination, is required for full ERM transcriptional activity. In this view, polyubiquitinated forms might be targeted for degradation, whereas a transient state of mono-ubiquitination might regulate protein activity before its targeting for degradation. Ubiquitination has been linked to the regulation of the activity of some transcription factors (Bres et al., 2003; Greer et al., 2003; Peloponese et al., 2004; Muratani et al., 2005) . Furthermore, ubiquitination is reported to be essential to the activity of the TADs of the VP16 and Tat proteins (Salghetti et al., 2001; Bres et al., 2003) , and ubiquitination of these TADs has been shown to increase their interaction with the positive transcription elongation factor b (P-TEFb), thus augmenting the rate of transcription elongation (Kurosu and Peterlin, 2004) . In this regard, it is noteworthy that the effects of ALLN and of K 48 R Ub depend on the presence of the Nterminal TAD, which belongs, like the VP16 TAD, to the acidic TAD class; it has been postulated that these two transactivating domains might be functionally related (Laget et al., 1996) . It will now be interesting to test whether the N-terminal TAD of ERM conjugates with Ub and associates with P-TEFb to enhance transcription. Alternatively, we cannot exclude the possibility that enhanced transcription mediated by ERM is related, at least in part, to co-activators whose activity or levels might be affected by inhibition of the proteasome or ubiquitination. It will also be important to identify the ubiquitination sites on ERM to precise the role of ERM ubiquitination in transcriptional activation.
Like many transcription factors, ERM is a target of several post-translational modifications that regulate its transcriptional activity. Of these, one has recently emerged as a major mechanism for inhibiting ERMmediated transcription; sumoylation, which has been shown to negatively affect the protein's capacity to activate transcription (Degerny et al., 2005) . ERM thus serves as a substrate for both ubiquitination and sumoylation, which probably control its properties in opposite manners. Crosstalk between the SUMO and Ub conjugation systems can thus be suspected. Preliminary results indicate that ERM mutated at the five lysine residues lying within consensus sumoylation sites remains significantly ubiquitinated. This suggests that the two types of modification do not involve the same lysine residues (data not shown). Yet we cannot exclude that SUMO modification of ERM might affect ubiquitination of the modified protein at other lysine residues, as part of a mechanism mediating transcriptional silencing. Whether deregulation in ERM modification pathways contributes to the role of this transcription factor in breast cancer metastasis remains to be elucidated.
Materials and methods
Plasmid constructs
The full-length pSG5-ERM expression vector, the aminoterminally truncated (ERM 87-510 (ERMDNt), ERM 276-510 , ERM ) and the carboxy-terminally truncated (ERM 1-449 (ERMDCt), ERM 1-370 , ERM 1-226 ) pSG5-ERM expression vectors have been described elsewhere (Janknecht et al., 1996; de Launoit et al., 1998) . The following truncated ERM proteins were generated from constructs produced by PCR: ERM 1-370/449-510 , ERM 1-90/293-510 and ERM 1-90/293-449 (oligonucleotide sequences are available on request). All PCR products were cloned into the pCRII vector, entirely sequenced and then cloned into the pSG5 vector (ERM 1-370/449-510 ) or the pSV-HA vector (ERM 1-90/293-510 and ERM 1-90/293-449 ) (Laget et al., 1996) using restriction sites introduced into the PCR primers. The full-length pSV-HA-ERM expression vector has been described previously (Baert et al., 2002) and so are the pGAP-Ct ERM vector expressing the 147 residues of the GAL4 DNA-binding domain fused to the C-terminal domain of ERM residues 449-510 and the GAL4 reporter construct containing five copies of the GAL4 binding sequence . Wt and mutated (K 48 R and K 63 R) His 6 -tagged Ub expression plasmids were kindly provided by Dr M Benkirane (CNRS-UPR 1142, Montpellier, France) (Bres et al., 2003) . As Ets-responsive luciferase reporter plasmid, we used the ICAM WT -Luc (ICAM) plasmid corresponding to the human ICAM-1 promoter fragment (bp À44 to À178) (de Launoit et al., 1998) . pSV2-Luc (SV40 promoter), pCMV-Luc (CMV promoter) and pEFIN-Luc (EF1a promoter) reporter plasmids were also used (Maurer et al., 2003) . The pSG5-b-galactosidase vector was used to normalize transfection (Baert et al., 2002) .
Cell cultures and transfections
Rabbit kidney cells (RK13), monkey kidney cells (COS-7), human U2OS osteosarcoma cells and MDA-MB-231 breast cancer cells were maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% (v:v) heat-inactivated fetal calf serum (Gibco BRL, Carlsbad, CA, USA) and cultured at 371C in a water-saturated 5% CO 2 atmosphere. 1.5 Â 10 5 cells/well were plated in 12-well plates, and the next day transient transfections were performed using the PEI Exgen 500 procedure (Euromedex, Souffelweyersheim, France) with 250 ng total DNA per well, including 100 ng reporter plasmid, 10 ng pSG5 expression vector and 10 ng b-galactosidase expression vector. Luciferase activity was determined 24 h after transfection and normalized with respect to the b-galactosidase activity (used as a measure of the transfection efficiency) as previously described (Degerny et al., 2005) . The data presented are means7s.e.m. of at least three independent experiments. To detect ERM or Ub-modified forms of ERM, we transfected COS-7, U2OS or RK13 cells with 300 ng/well (six-well plates) of ERM expression plasmid and, when indicated, with 700 ng plasmid coding for wt or mutated His 6 -tagged-Ub. After 24 h, the cells were rinsed with phosphate-buffered saline (PBS) and lysed in immunoblot or Ni 2 þ purification buffer.
Western blot analysis
Transfected cells, either untreated or treated with a proteasome inhibitor (ALLN: 50 mM, 5 h; MG132: 40 mM, 5 h; or lactacystin: 10 mM, 5 h) or with cycloheximide (80 mg/ml), were washed twice with PBS and lysed in Laemmli gel loading buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 5% b-mercaptoethanol, 10% sucrose). After separation by SDS-PAGE, the proteins were transferred to nitrocellulose membranes. Immunoblot analyses were performed with rabbit anti-ERM antibodies (anti-ERM 12-226 or anti-ERM 355-510 ; Janknecht et al., 1996) , anti-Gal4 antibody or anti-actin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), followed by treatment with horseradish peroxidase-conjugated secondary antibody. Immune complexes were visualized by enhanced chemiluminescence according to the manufacturer's instructions (Santa Cruz Biotechnology).
Identification of His-Ub-ERM conjugates
Transfected cells were lysed in denaturing buffer containing 6 M guanidium-HCl. His 6 -Ub conjugates were purified by Metal-Chelate Affinity Chromatography as described previously (Degerny et al., 2005) . Briefly, cells plated in six-well plates were washed twice in ice-cold PBS and lysed in 400 ml lysis buffer (6 M guanidium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 pH 8.0, 0.01 M Tris-HCl pH 8.0) per 35-mm well. The lysates were centrifuged at 100 000 g for 90 min at 41C. Each sample was mixed with 20 ml packed Ni 2 þ -NTA beads (Qiagen, Valencia, CA, USA) and rotated for 3 h at room temperature. The beads were then washed twice with lysis buffer, three times with 8 M urea, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 (pH 6.4) and once with PBS before being resuspended in Laemmli gel loading buffer and analysed by SDS-PAGE. Proteins were then electrophoretically transferred to nitrocellulose membranes and His-Ub conjugates were detected with an appropriate antibody as described above.
Labeling of cells and immunoprecipitation
MDA-MB-231 cells were allowed to grow for 40 h before labeling. Cells were then placed in Met/Cys-free DMEM for 2 h, after which 100 mCi 35 S labeledMet/Cys per ml was added to the medium. After 3 h, the cells were washed with PBS and incubated in medium supplemented with unlabeled Met for the time indicated. Cell lysis and immunoprecipitation with anti-ERM antibody were then performed as described previously (Baert et al., 2002) . Immunocomplexes were finally eluted in Laemmli gel loading buffer, separated by SDS-PAGE and autoradiographed.
